Full-Time

Workplace Strategy and Planning Lead

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

Compensation Overview

$122.4k - $227.2k/yr

+ Discretionary annual bonus

Pleasanton, CA, USA + 1 more

More locations: Santa Clara, CA, USA

In Person

Relocation support is not available.

Bachelor's

Category
Facilities Operations (1)
Required Skills
GMP

Get referred to Roche

See people who can refer or advise you

Requirements
  • A bachelor's degree in Architecture, Engineering, Project Management, or a related field is required, along with at least 5 years of experience in workplace design, space planning, or facilities management.
  • At least 3 years of experience managing laboratory space portfolios in a pharmaceutical or life sciences setting is required.
  • Working knowledge of laboratory design standards, safety regulations including biological safety levels and chemical fume hoods, and Good Manufacturing Practice and Good Laboratory Practice compliance is required.
  • A proven track record leading cross-functional teams and managing end-to-end capital project deliverables with budgets up to $5 million is required.
  • Proficiency with Integrated Workplace Management Systems or laboratory-specific tools such as Laboratory Information Management Systems and equipment-tracking systems is required to analyze occupancy metrics and execute space-allocation workflows.
  • The ability to collaborate directly with scientific leadership, research and development teams, and global facility partners is required.
  • Demonstrated experience driving workplace-experience initiatives, communication plans, and occupancy transitions is required to minimize operational disruption.
Responsibilities
  • Direct all project delivery phases, including budgets up to $5 million, vendor coordination, and timelines, for new construction and renovations across office and laboratory environments.
  • Lead interior and exterior space-optimization strategies, ensuring laboratory designs meet scientific requirements, biosafety and Good Laboratory Practice and Good Manufacturing Practice standards, and operational workflows.
  • Manage campus laboratory space assignments, track utilization metrics, and make data-driven recommendations for capacity planning and reallocation.
  • Maintain campus workplace policies, design guidelines, and safety and ergonomic standards in partnership with research and development, Safety, Health and Environment, and Quality teams.
  • Develop and execute comprehensive change-management and transition plans to maximize adoption of new workspace strategies with minimal business disruption.
  • Collaborate with local and global partners to align capital projects with campus master planning and long-term strategic research and development objectives.
  • Oversee sustainability, furniture reuse, and donation programs to align with corporate environmental and safety goals.
Desired Qualifications
  • Working knowledge of Good Manufacturing Practice and Good Laboratory Practice compliance is preferred.
  • Project Management Professional certification is preferred.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 sales rose 6% at constant exchange rates; core profit rose 10%.
  • FDA cleared Elecsys pTau217 on August 24, 2026, unlocking Alzheimer testing at scale.
  • Tam-Peli’s 54% death-risk reduction and global phase III plans strengthen oncology growth.

What critics are saying

  • Biocon’s Perjeta biosimilar lawsuit in New Jersey threatens Herceptin-like erosion by 2027.
  • Genentech disclosed 2026 layoffs, signaling ongoing restructuring and stalled internal productivity.
  • Swiss franc strength cut H1 2026 reported sales 2%, pressuring earnings translation again.

What makes Roche unique

  • Roche’s 4,500 US cobas instruments make Elecsys pTau217 instantly scalable.
  • Roche pairs pharmaceuticals and diagnostics, creating bundled disease franchises competitors cannot match.
  • Genentech gives Roche deep biologics R&D and patented oncology manufacturing depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.

Yahoo Finance
Sep 1st, 2026
Roche commits $75M upfront in blood cancer deal worth up to $1.53B

Roche has committed $75 million upfront to acquire global rights to Simcere Pharmaceutical's experimental blood-cancer drug SIM0660. The deal could reach $1.53 billion if the drug meets development, regulatory and commercial milestones, with additional tiered royalties. The agreement grants Roche exclusive development, manufacturing and commercialisation rights outside Simcere's retained markets. The upfront payment represents just 4.9% of the deal's total potential value. SIM0660 remains in preclinical stages. Roche generated CHF11.9 billion in core operating profit during the first half of the year. The company's US-quoted shares fell to $53.55 on Tuesday following the announcement.

Yahoo Finance
Aug 25th, 2026
CVS and Roche stocks could benefit from expanding GLP-1 drug market

CVS Health and Roche could benefit from the growing GLP-1 drug market, alongside current leaders Eli Lilly and Novo Nordisk. CVS Health has improved its financial performance, with second-quarter revenue rising 7.3% year-over-year to $106.1 billion and adjusted earnings per share increasing 42.5% to $2.58. The pharmacy chain offers all approved GLP-1 medicines in the US, including Eli Lilly's Zepbound and Foundayo, plus Novo Nordisk's Wegovy. CVS also provides low-cost online consultations at $29 to assess patient eligibility for GLP-1 drugs. Beyond GLP-1 initiatives, CVS is addressing previous business challenges and is positioned to capitalise on rising healthcare spending in the US over the next decade.

Yahoo Finance
Aug 24th, 2026
Roche and Eli Lilly win FDA clearance for Alzheimer's blood test for over-55s

Roche and Eli Lilly have received FDA clearance for a blood test that helps detect signs of Alzheimer's disease in people aged 55 and older experiencing cognitive decline. The Elecsys pTau217 test measures a blood biomarker to determine whether patients are likely to have brain changes associated with Alzheimer's. The test can be performed using more than 4,500 Roche laboratory analysers already installed across the United States. Labcorp and Quest Diagnostics plan to offer the test through their laboratory networks, expanding access nationwide. Pricing has not been disclosed. The clearance follows European approval in May. Blood-based testing could provide a simpler alternative to existing methods like PET imaging and cerebrospinal fluid analysis, which can be expensive and invasive.